RT Journal Article
SR Electronic
T1 An integrated multi-omics analysis identifies clinically relevant molecular subtypes of non-muscle-invasive bladder cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.19.20054809
DO 10.1101/2020.06.19.20054809
A1 Sia Viborg Lindskrog
A1 Frederik F. Prip
A1 Philippe Lamy
A1 Ann Taber
A1 Clarice S. Groeneveld
A1 Karin Birkenkamp-Demtröder
A1 Jørgen Bjerggaard Jensen
A1 Trine Strandgaard
A1 Iver Nordentoft
A1 Emil Christensen
A1 Mateo Sokac
A1 Nicolai J. Birkbak
A1 Lasse Maretty
A1 Gregers G. Hermann
A1 Astrid C. Petersen
A1 Veronika Weyerer
A1 Marc-Oliver Grimm
A1 Marcus Horstmann
A1 Gottfrid Sjödahl
A1 Mattias Höglund
A1 Torben Steiniche
A1 Karin Mogensen
A1 Aurélien de Reyniès
A1 Roman Nawroth
A1 Brian Jordan
A1 Xiaoqi Lin
A1 Dejan Dragicevic
A1 Douglas G. Ward
A1 Anshita Goel
A1 Carolyn D. Hurst
A1 Jay D. Raman
A1 Joshua I. Warrick
A1 Ulrika Segersten
A1 Danijel Sikic
A1 Kim E.M. van Kessel
A1 Tobias Maurer
A1 Joshua J. Meeks
A1 David J. DeGraff
A1 Richard T. Bryan
A1 Margaret A. Knowles
A1 Tatjana Simic
A1 Arndt Hartmann
A1 Ellen C. Zwarthoff
A1 Per-Uno Malmström
A1 Núria Malats
A1 Francisco X. Real
A1 Lars Dyrskjøt
YR 2020
UL http://medrxiv.org/content/early/2020/06/22/2020.06.19.20054809.abstract
AB The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized by large biological heterogeneity with variable clinical outcomes. Here, we performed a large integrative multi-omics analysis of patients diagnosed with NMIBC (n=834). Transcriptomic analysis identified four classes (1, 2a, 2b and 3) reflecting tumor biology and disease aggressiveness. Both transcriptome-based subtyping and the level of chromosomal instability provided independent prognostic value beyond established prognostic clinicopathological parameters. High chromosomal instability, p53-pathway disruption and APOBEC-related mutations were significantly associated with transcriptomic class 2a and poor outcome. RNA-derived immune cell infiltration was associated with chromosomally unstable tumors and enriched in class 2b. Spatial proteomics analysis confirmed the higher infiltration of class 2b tumors and demonstrated an association between higher immune cell infiltration and lower recurrence rates. Finally, a single-sample classification tool was built and the independent prognostic value of the transcriptomic classes was documented in 1306 validation samples. The classifier provides a framework for novel biomarker discovery and for optimizing treatment and surveillance in next-generation clinical trials.Competing Interest StatementL.D. has sponsored research agreements with C2i-genomics, Natera, AstraZeneca and Ferring, and has an advisory/consulting role at Ferring. J.B.J. has sponsored research agreements with Medac, Photocure ASA, Cephaid, Nucleix, Astellas and Ferring, and has an advisory board role at Olympus Europe, Cephaid and Ferring. J.D.R. is involved in a sponsored scientific study or trial with Pacific Edge Biotechnologies, MDxHealth and Urogen Pharma, is a consultant for Urogen Pharma, and has an investment interest in American Kidney Stone Management. J. J. M. is a consultant for Ferring, AstraZeneca, Janssen and participated in advisory boards for Foundation Medicine and Nucleix.Funding StatementFunding: SVL, FFP, and LD are supported by the following funding sources: Aarhus University, The Danish Cancer Biobank, The Health Research Foundation of Central Denmark Region, The Danish Cancer Society. NM and FXR are supported by Fondo de Investigaciones Sanitarias (FIS), Instituto de Salud Carlos III, Spain (#PI18/01347), Asociacion Espanola Contra el Cancer (AECC, # GB28012014). DJD is supported by the following funding sources: RSG 17 233 01 TBE from the American Cancer Society, the W.W. Smith Charitable Trust, the Pennsylvania Department of Health via Tobacco CURE Funds, the Ken and Bonnie Shockey Fund for Urologic Research and the Bladder Cancer Support Group at Penn State Health. JIW is supported by the Laurence M. Demers Career Development Professorship in Pathology and Medicine, Pennsylvania State University. JDR is supported by the Ken and Bonnie Shockey Fund for Urologic Research at Penn State Health. JM is funded by a SEED Award from the HOPE Foundation, the Department of Defense (W81XWH-18-0257), and the VHA (BX003692-01). Ethichal review boards: The study was approved by the Central Denmark Region Committees on Biomedical Research Ethics (#1994/2920; Skejby, Aalborg, Frederiksberg); the Danish National Committee on Health Research Ethics (#1906019), the ethics committee of the University Hospital Erlangen (#3755); the ethics committee of the Technical University of Munich (#2792/10); Medical Ethics Committee of Erasmus MC (MEC#168.922/1998/55; Rotterdam); the Uppsala Region Committee on Biomedical Research Ethics (#2008/252); the Ethical Committee of Faculty of Medicine, University of Belgrade (#440/VI-7); the Ethics Committee (CEIC) of Institut Municipal dAssistencia Sanitaria/Hospital del Mar (2008/3296/I); the ethics committee of the University Hospital Jena (#4774-4/16).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNormalized RNA read counts (accession# to be included, submission in progress) and SNP microarray data (accession# to be included, submission in progress) are deposited at the European Bioinformatics Institute (EMBL-EBI) Array Express. Raw sequencing data is deposited at The European Genome-phenome Archive (EGA) under accession numbers EGAS00001001236 and EGASxx (submission in progress). There are restrictions to the availability of raw sequencing data deposited at EGA due to Danish legislation regarding sharing and processing of sensitive personal data. Data can be shared if the new research purposes proposed by the data importers are approved by the National Committee on Health Research Ethics in Denmark. Furthermore, data processor agreements and contracts need to be signed to fulfil European GDPR data sharing rules. The lead contact will accommodate reasonable requests. Processed (non-sensitive) data will be shared upon request without restrictions.